Clozapine, neutropenia and Covid-19: should clinicians be concerned? 3 months report.

ABSTRACT:

Background

Clozapine is among the most effective antipsychotics used for treatment resistant schizophrenia. Adverse reactions to clozapine include neutropenia. In March 2020, at the start of the Coronavirus -19 pandemic, clinicians raised concerns regarding continuation of antipsychotic treatment, and specifically of clozapine, in patients with coronavirus disease. We aimed here at providing a short report focusing on the association between neutropenia and clozapine in a case series of psychiatric inpatients diagnosed with COVID-19.

Patients & methods

We retrospectively inspected data of 10 patients on clozapine, admitted to Highgate Mental Health Centre, Camden & Islington NHS Foundation Trust, between March and July 2020; selection was based on their COVID-19 positive PCR

SUBMITTER: Bonaccorso S 

PROVIDER: S-EPMC7840406 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature